MignonL.LohMD

Pediatric Hematology & Oncology • Seattle, WA

Chief, Division of Pediatric Hematology, Oncology, Bone Marrow Transplant and Cellular Therapy & Director, Ben Towne Center for Childhood Cancer

Join to view full profile

Dr. Loh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Loh's full profile

Already have an account?

Office
4800 Sand Point Way NE
MB.8.501
Seattle, WA 98105
Phone+1 206-987-2106

Summary

Dr. Mignon Loh is center director for the Ben Towne Center for Childhood Cancer Research and chief of the Division of Pediatric Hematology, Oncology, Bone Marrow Transplant and Cellular Therapy, overseeing the Cancer and Blood Disorders Center at Seattle Children’s Hospital. Her research focuses on how and why leukemia progresses, as well as making genomics discoveries in the lab that translate into new and better diagnostics and therapeutics for children, adolescents and young adults with leukemia.

Education & Training

Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1995 - 1998
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1992 - 1994
University of California (San Francisco)Internship, Pediatrics, 1991 - 1992
Columbia University Vagelos College of Physicians and SurgeonsClass of 1991

Certifications & Licensure

WA State Medical License 2021 - 2026
CA State Medical License 1999 - 2025
MA State Medical License 1994 - 2001
NC State Medical License 1995 - 1998
NY State Medical License 1994 - 1996
CT State Medical License 1994 - 1995
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma Start of enrollment: 2004 Nov 01
Terminated
Phase 2
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2003 Dec 01
Completed
Studying DNA in Blood and Bone Marrow Samples From Young Patients With Acute Lymphoblastic Leukemia Start of enrollment: 2009 Nov 01
Completed
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Start of enrollment: 2010 Sep 01
Completed
Phase 1
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene Start of enrollment: 2014 May 01
Completed
Phase 1
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia Start of enrollment: 2016 Sep 30
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

6 citations
Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity.
Yiwei Liu, Wenjian Yang, Colton Smith, Cheng Cheng, Seth E. Karol
Clinical Pharmacology and Therapeutics. 2021-09-01
28 citations
Remission, treatment failure, and relapse in pediatric ALL: An international consensus of the Ponte-di-Legno Consortium.
Swantje Buchmann, Martin Schrappe, André Baruchel, Andrea Biondi, Michael J. Borowitz
Blood. 2021-06-30
20 citations
Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia.
Yizhen Li, Wentao Yang, Meenakshi Devidas, Stuart S. Winter, Chimene Kesserwan
The Journal of Clinical Investigation. 2021-06-24

Journal Articles

Inotuzumab Ozogamicin in Pediatric Patients with relapsed/refractory Acute Lymphoblastic Leukemia
Deepa Bhojwani, Constance Yuan, Jennifer L McNeer, Mignon L Loh, Vilmarie Rodriguez, Susan R Rheingold, Elizabeth A Raetz, Nature
Downregulating Notch Counteracts KrasG12D-Induced ERK Activation and Oxidative Phosphorylation in Myeloproliferative Neoplasm
Erik A Ranheim, David Yang, Warren S Pear, Lan Zhou, Mignon Loh, Eric Padron, Elliot Stieglitz, Nature
Mutation-Specific Signaling Profiles and Kinase Inhibitor Sensitivities of Juvenile Myelomonocytic Leukemia Revealed by Induced Pluripotent Stem Cells
Stella T Chou, Jessica A Casas, Mignon L Loh, Sarah K Tasian, Nature
Genomic and Outcome Analyses of Ph-like ALL in NCI Standard-Risk Patients: A Report from the Children's Oncology Group
Michael J Borowitz, Nyla A Heerema, Brent L Wood, Elizabeth A Raetz, Stephen P Hunger, Andrew J Carroll, Mignon L Loh, Cheryl L Willman, Kelly W Maloney, Blood
Genomic Analyses Identify Recurrent MEF2D Fusions in Acute Lymphoblastic Leukaemia
Michael Borowitz, Hagop M Kantarjian, Cheryl L Willman, Stephen P Hunger, Selina M Luger, Clara D Bloomfield, Brent Wood, Jerald P Radich, Marina Konopleva, Stephen J ..., Nature
Join now to see all

Abstracts/Posters

Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the ChildrenÍs...
Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia
Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Identification of New Risk Loci and Regulatory Mechanisms Influencing Genetic Susceptibility to Acute Lymphoblastic Leukaemia
Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis from the Ponte Di Legno Childhood ALL Working Group
Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid...
Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Germline RUNX1 Variation and Predisposition to T-Cell Acute Lymphoblastic Leukemia in Children
Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results fro...
Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631...
Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or...
Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
RUNX2 Regulates Cell Migration in T-Cell Lineage Acute Lymphoblastic Leukemia
Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic ...
Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation
Mignon L. Loh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Using Genomics to Risk Stratify and Treat Kids
60th American Society of Hematology Annual Meeting - 12/2/2018
Using Genomics to Risk Stratify and Treat Kids
60th American Society of Hematology Annual Meeting - 12/1/2018
Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clini...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Taking Stock of Breakthroughs and Struggles in Pediatric Cancer CareJuly 1st, 2022
Seattle Children’s Welcomes Dr. Mignon Loh to Lead Cancer and Blood Disorders Care and ResearchFebruary 1st, 2022
IU Researcher Leads National Work Focused on Developing Treatments for Inherited Childhood CancersNovember 18th, 2021
Join now to see all

Grant Support

International Symposium On Juvenile Myelomonocytic Leukemia (JMML)National Cancer Institute2011
International Symposium On Juvenile Myelomonocytic Leukeumia (JMML)National Cancer Institute2010
Identifying The Spectrum Of Genetic Alterations In High Risk AllNational Cancer Institute2010
Targeted Therapies For Childhood Acute Lymphoblastic LeukemiaNational Cancer Institute2009–2010
International Symposium On Juvenile Myelomonocytic LeukemiaNational Cancer Institute2007–2009
RAS Pathway Mutations In Human LeukemiaNational Cancer Institute2006–2008
OPEN Label, Phase I/II Trial Of Rituximab For Chronic, Severe ITPNational Center For Research Resources2004–2005
Fusion Genes In Leukemia--Determining SignificanceNational Cancer Institute1999–2003
Fusion Genes In Leukemia--Determining SignificanceNational Cancer Institute1999